Written and maintained by CASRAI Editorial Board
Last updated
CMS NTAP (New Technology Add-On Payment) is a statutory supplemental reimbursement mechanism within the Medicare Hospital Inpatient Prospective Payment System (IPPS)—authorized under Section 1886(d)(5)(K) and (L) of the Social Security Act and codified at 42 CFR § 412.87 and § 412.88—that provides temporary additional payments (for up to 2 to 3 years) to acute care hospitals when they use qualifying high-cost, clinically transformative new medical devices, diagnostics, therapeutics, or Software as a Medical Device (SaMD) / clinical AI systems during an inpatient hospital stay.
Under standard Medicare IPPS rules, a hospital receives a single bundled payment per inpatient discharge based on the assigned Medicare Severity Diagnosis-Related Group (MS-DRG). Because CMS recalibrates MS-DRG relative weights using historical hospital claims data that lag by two to three years, newly FDA-authorized technologies are not yet reflected in the base MS-DRG payment—creating a financial disincentive for hospitals to adopt breakthrough technologies. NTAP bridges this 2–3 year data lag until utilization costs are absorbed into standard MS-DRG weights.
What Is NTAP CMS and What Standards Govern Eligibility? (42 CFR § 412.87)
To receive a New Technology Add-On Payment designation in the annual CMS Hospital IPPS Final Rule (effective October 1 at the start of the federal Fiscal Year), a manufacturer must submit an application through the CMS MEARIS (Medicare Electronic Application Request Information System) portal and satisfy either the Traditional Three-Prong Pathway (42 CFR § 412.87(b)) or the Alternative Breakthrough / Antimicrobial Pathway (42 CFR § 412.87(c)–(d)):
| NTAP Eligibility Criterion | CFR Citation | Traditional Pathway Requirement (§ 412.87(b)) |
Alternative Pathway Rule (Breakthrough Device § 412.87(c) / QIDP-LPAD § 412.87(d)) |
|---|---|---|---|
| 1. Not Substantially Similar & Newness Window (2–3 Years) | 42 CFR § 412.87(b)(2) |
The medical service or technology must not be “substantially similar” to an existing technology (evaluated across mechanism of action, MS-DRG assignment, and target disease/patient population) and must be within its 2- to 3-year newness period starting on the date of FDA market authorization (or commercial market availability). | Waived for initial eligibility: Technologies holding an active FDA Breakthrough Device Designation (Section 515B) or FDA Qualified Infectious Disease Product (QIDP) / Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) approval are automatically deemed “new” and not substantially similar. |
| 2. Cost Criterion (Inadequacy of MS-DRG Payment) | 42 CFR § 412.87(b)(3) |
The average case-weighted standardized charge per inpatient case involving the new technology must exceed the published CMS MS-DRG Cost Criterion Threshold (specifically, the lesser of 75% of one standard deviation beyond the geometric mean standardized charge for all cases in the MS-DRG, or 75% of one standard deviation beyond the geometric mean standardized charge across all cases in the parallel MS-DRG group). | Still Strictly Required: Even FDA Breakthrough Devices and QIDP/LPAD drugs must satisfy the § 412.87(b)(3) Cost Criterion to qualify for NTAP. |
| 3. Substantial Clinical Improvement (SCI) | 42 CFR § 412.87(b)(1) |
The applicant must present peer-reviewed clinical evidence demonstrating that the technology represents an advance that substantially improves, relative to technologies previously available, the diagnosis or treatment of Medicare beneficiaries. | Waived: FDA Breakthrough Devices (`§ 412.87(c)`) and QIDP/LPAD antimicrobials (`§ 412.87(d)`) are exempt from proving Substantial Clinical Improvement independently to CMS. |
| 4. FDA Marketing Authorization Cutoff | 42 CFR § 412.87(f) |
The technology must have a complete, active FDA marketing application at the time of MEARIS submission and receive final FDA approval/clearance by May 1 prior to the October 1 IPPS Fiscal Year effective date. | May 1 FDA authorization deadline applies to standard and Breakthrough Device applications; July 1 deadline applies to QIDP/LPAD antimicrobial applications. |
How CMS Evaluates “Substantial Clinical Improvement” (SCI) for Diagnostics and AI
Under 42 CFR § 412.87(b)(1), CMS evaluates whether a non-Breakthrough diagnostic, device, or clinical AI algorithm achieves Substantial Clinical Improvement across three statutory benchmarks:
- Unmet Clinical Population: The technology offers a treatment or diagnostic option for a Medicare patient population unresponsive to, or ineligible for, currently available treatments.
- Actionable Earlier or More Accurate Diagnosis: The technology offers the ability to diagnose a medical condition in a patient population where that condition is currently undetectable, or offers the ability to diagnose a medical condition earlier in the course of the disease than existing methods—and there is empirical clinical evidence that making such a diagnosis affects the management of the patient (for example, significantly shortening door-to-groin-puncture time in endovascular thrombectomy for acute ischemic stroke).
- Superior Clinical Outcomes: Use of the technology significantly improves clinical outcomes compared to existing alternatives, demonstrated by at least one of the following: (a) reduction in mortality rate, (b) reduction in device-related complications, (c) decreased rate of subsequent diagnostic or therapeutic interventions, (d) decreased post-discharge hospital readmissions or emergency department visits, (e) accelerated recovery or reduced ICU/hospital length of stay, or (f) improved quality of life / functional outcome scores.
The 42 CFR § 412.88 NTAP Payment Calculation Formula & Worked Example
A critical operational feature of CMS NTAP is that hospitals are not automatically paid the maximum NTAP cap on every claim. Instead, under 42 CFR § 412.88(a)(2), Medicare only pays an add-on when the hospital’s estimated operating cost for that specific inpatient stay exceeds the standard bundled MS-DRG payment—and even then, CMS shares the marginal cost rather than reimbursing 100%:
NTAP Payment = MIN( 0.65 × [Estimated Case Operating Cost − Base MS-DRG Payment], 0.65 × Manufacturer Reported Cost of Technology )
(Note: For QIDP and LPAD antimicrobial drugs under § 412.88(b), the marginal sharing percentage is 75% rather than 65%.)
Worked Hospital Claim Arithmetic Example
Suppose CMS approves a new inpatient diagnostic/therapeutic technology with a manufacturer-reported cost of $3,200, setting the Maximum NTAP Cap at $2,080 (0.65 × $3,200):
- Step 1 — Determine Base MS-DRG Payment: The patient is discharged under an acute ischemic stroke MS-DRG with a hospital-specific base operating payment of $14,000.
- Step 2 — Convert Total Claim Charges to Operating Cost: The hospital submits a UB-04 (X12 837I) inpatient claim with total covered charges of $42,500, and the hospital’s overall operating Cost-to-Charge Ratio (CCR) on its Medicare cost report is 0.40. The Medicare Administrative Contractor (MAC) PRICER calculates the estimated operating cost of the stay as
$42,500 × 0.40 = $17,000. - Step 3 — Calculate Case Cost Excess Over MS-DRG: Because the estimated case cost (
$17,000) exceeds the base MS-DRG payment ($14,000), the excess cost is$17,000 − $14,000 = $3,000. - Step 4 — Apply the Lesser-Of 65% Rule:
- 65% of the case cost excess:
0.65 × $3,000 = $1,950. - Maximum NTAP Cap (65% of technology cost):
$2,080. - Actual NTAP Add-On Paid on Claim:
MIN($1,950, $2,080) = $1,950(bringing total hospital reimbursement before outlier/IME/DSH adjustments to$14,000 + $1,950 = $15,950).
- 65% of the case cost excess:
How Does NTAP CMS Integrate with Hospital EHR, ICD-10-PCS Coding, and Clinical AI Workflows?
In September 2020 (for FY 2021), CMS approved the first-ever NTAP for artificial intelligence software—Viz.ai’s Viz LVO computer-aided triage and notification (CADt) software for suspected large vessel occlusion stroke (with a maximum add-on of $1,040 per eligible inpatient stay)—followed by subsequent NTAP designations for radiology AI and acute care triage algorithms (including Aidoc and RapidAI):
- ICD-10-PCS Procedure Code Assignment: Because inpatient hospital claims (X12 837I / UB-04) do not use outpatient CPT codes to calculate MS-DRG or NTAP payments, the manufacturer must apply to the CMS ICD-10 Coordination and Maintenance Committee for a dedicated ICD-10-PCS procedure code—frequently placed in Section X (New Technology) or Section 4 (Measurement and Monitoring, such as
4A03X5Dfor intracranial arterial flow computer-aided assessment). - Automated EHR Charge/Procedure Triggering: When an inpatient or emergency-to-inpatient admitted patient’s CT angiogram or physiological stream is analyzed by an NTAP-eligible AI system, a mere background PACS alert will be missed by hospital inpatient coders unless the AI platform writes a structured HL7/FHIR procedure note or discrete order-completion event into the EHR chart (e.g., Epic or Oracle Health) that triggers the corresponding ICD-10-PCS code on the UB-04 claim.
- Relationship to Outpatient and Coverage Pathways: While NTAP covers the inpatient hospital setting (`42 CFR § 412.87`), manufacturers pair it with the Hospital Outpatient Prospective Payment System (OPPS) Transitional Pass-Through Payment (`42 CFR § 419.66`) or New Technology APCs for outpatient encounters, and coordinate evidence generation with Medicare device coverage pathways (NCD, TCET, and CED) and Coverage with Evidence Development (CED).
Frequently Asked Questions
What is NTAP CMS and how is it used in clinical research and healthcare?
CMS NTAP (New Technology Add-On Payment), codified at 42 CFR § 412.87–412.88, is a Medicare Inpatient Prospective Payment System (IPPS) mechanism that pays acute care hospitals up to 65% of the marginal cost (75% for QIDP/LPAD antimicrobials) of qualifying new medical devices, drugs, diagnostics, and clinical AI software for 2 to 3 years while CMS collects claims data to recalibrate standard MS-DRG weights. In clinical research, demonstrating NTAP’s “Substantial Clinical Improvement” (SCI) criterion drives prospective real-world outcomes studies measuring time-to-treatment, complication reduction, and length of stay.
What standards or regulatory requirements govern NTAP CMS?
NTAP is governed by Section 1886(d)(5)(K)–(L) of the Social Security Act and 42 CFR § 412.87–412.88. Under the traditional pathway, technologies must receive FDA marketing authorization by May 1 and prove Newness (within 2–3 years of market entry), Cost (exceeding the MS-DRG standardized charge threshold), and Substantial Clinical Improvement (SCI). Technologies holding an FDA Breakthrough Device Designation (§ 412.87(c)) or QIDP/LPAD antimicrobial approval (§ 412.87(d)) are exempt from the Newness and SCI criteria and need only satisfy the Cost criterion and FDA authorization deadline.
How does NTAP CMS integrate with EHR and health informatics workflows?
Because Medicare inpatient claims are adjudicated via the IPPS PRICER using ICD-10-PCS procedure codes on the UB-04 (X12 837I) institutional claim rather than CPT codes, NTAP-eligible technologies—especially radiology and clinical AI triage algorithms—must integrate with the hospital’s EHR and Computer-Assisted Coding (CAC) workflow to document a discrete clinical note or HL7/FHIR procedure event that prompts HIM coders to assign the specific ICD-10-PCS New Technology code on the inpatient claim.
